These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32492724)

  • 1. Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective.
    Spyropoulos AC; Ageno W; Cohen AT; Gibson CM; Goldhaber SZ; Raskob G
    Thromb Haemost; 2020 Jun; 120(6):924-936. PubMed ID: 32492724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
    Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
    Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
    Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
    Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era.
    MacDougall K; Spyropoulos AC
    Semin Respir Crit Care Med; 2021 Apr; 42(2):308-315. PubMed ID: 33548931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New paradigms in venous thromboprophylaxis of medically ill patients.
    Spyropoulos AC; Raskob GE
    Thromb Haemost; 2017 Aug; 117(9):1662-1670. PubMed ID: 28640324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
    J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients.
    Spyropoulos AC
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):506-514. PubMed ID: 36485109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
    Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
    J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis.
    Miao B; Chalupadi B; Clark B; Descoteaux A; Huang D; Ilham S; Ly B; Spyropoulos AC; Coleman CI
    Clin Appl Thromb Hemost; 2019; 25():1076029619850897. PubMed ID: 31088302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.
    Raskob GE; Ageno W; Albers G; Elliott CG; Halperin J; Maynard G; Steg PG; Weitz JI; Albanese J; Yuan Z; Levitan B; Lu W; Suh EY; Spiro T; Lipardi C; Barnathan ES; Spyropoulos AC
    J Am Heart Assoc; 2022 Oct; 11(20):e026229. PubMed ID: 36205248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.
    Laskier V; Guy H; Fisher M; Neuman WR; Bucior I; Cohen AT; Ren S
    J Med Econ; 2019 Oct; 22(10):1063-1072. PubMed ID: 31314619
    [No Abstract]   [Full Text] [Related]  

  • 12. A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
    Snoga JL; Benitez RM; Kim S; Creager O; Lusk KA
    Am J Health Syst Pharm; 2021 Jun; 78(12):1057-1065. PubMed ID: 33580664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients.
    MacDougall K; Spyropoulos AC
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
    Raskob GE; Spyropoulos AC; Spiro TE; Lu W; Yuan Z; Levitan B; Suh E; Barnathan ES
    J Am Heart Assoc; 2021 Nov; 10(22):e021579. PubMed ID: 34755519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
    Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
    Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended duration of thromboprophylaxis for medically ill patients: a systematic review and meta-analysis of randomised controlled trials.
    Zayed Y; Kheiri B; Barbarawi M; Banifadel M; Abdalla A; Chahine A; Obeid M; Haykal T; Yelangi A; Malapati S; Bachuwa G; Seedahmed E
    Intern Med J; 2020 Feb; 50(2):192-199. PubMed ID: 31276276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.
    Veeranki SP; Xiao Z; Levorsen A; Sinha M; Shah BR
    Am J Cardiovasc Drugs; 2021 Jul; 21(4):443-452. PubMed ID: 33313988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux.
    Di Nisio M; Porreca E
    Drug Des Devel Ther; 2013; 7():973-80. PubMed ID: 24068866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous Thromboembolism Prophylaxis: A Narrative Review With a Focus on the High-Risk Critically Ill Patient.
    Lewis TC; Cortes J; Altshuler D; Papadopoulos J
    J Intensive Care Med; 2019; 34(11-12):877-888. PubMed ID: 30165770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis.
    Ageno W; Hunt BJ
    Eur Heart J Suppl; 2018 May; 20(Suppl E):E6-E11. PubMed ID: 29977163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.